 |
49 Diseases |  |
64 Trials |
|
64 Trials |  |
670 News |  |
| «1234567891011» |
- | Blincyto (blinatumomab) / Astellas, Amgen
Trial completion date, Trial primary completion date: SWOG-S1318: Blinatumomab and Combination Chemotherapy or Dasatinib, Prednisone, and Blinatumomab in Treating Older Patients With Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Sep 7, 2022
P2, N=57, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Trial completion date: Jun 2023 --> Sep 2023 | Trial primary completion date: Jun 2023 --> Jun 2022
- | Blincyto (blinatumomab) / Astellas, Amgen
Trial completion date, Trial primary completion date, Combination therapy: AALL1731: A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia (clinicaltrials.gov) - Sep 6, 2022
P3, N=6720, Recruiting, Sponsor: National Cancer Institute (NCI)
Trial completion date: Jun 2023 --> Sep 2023 | Trial primary completion date: Jun 2023 --> Jun 2022 Trial completion date: Dec 2027 --> Mar 2028 | Trial primary completion date: Dec 2027 --> Mar 2028
- | Yonsa (abiraterone acetate) / Churchill Pharma, Sun Pharma, Erleada (apalutamide) / J&J
Enrollment closed, Metastases: Abiraterone Acetate, Prednisone, and Apalutamide in Treating Patients With Hormone-Naive Metastatic Prostate Cancer (clinicaltrials.gov) - Aug 30, 2022
P2, N=60, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Trial completion date: Dec 2027 --> Mar 2028 | Trial primary completion date: Dec 2027 --> Mar 2028 Recruiting --> Active, not recruiting
- || Venclexta (venetoclax) / Roche, AbbVie, Blincyto (blinatumomab) / Astellas, Amgen, Rituxan (rituximab) / Roche
Enrollment open, Combination therapy: NCI-2021-01791: Venetoclax, Dasatinib, Prednisone, Rituximab and Blinatumomab for the Treatment of Newly Diagnosed or Relapsed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia or Mixed Phenotype Acute Leukemia (clinicaltrials.gov) - Aug 19, 2022
P1, N=20, Recruiting, Sponsor: OHSU Knight Cancer Institute
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- | Remicade (infliximab) / J&J
Trial completion date, Trial primary completion date, IO biomarker: ECOG-ACRIN-EAQ172: Infliximab and Intravenous Immunoglobulin Therapy in Treating Patients With Steroid-Refractory Pneumonitis (clinicaltrials.gov) - Aug 12, 2022
P2, N=36, Recruiting, Sponsor: ECOG-ACRIN Cancer Research Group
Not yet recruiting --> Recruiting Trial completion date: May 2024 --> Jan 2025 | Trial primary completion date: May 2024 --> Dec 2024
- || prednisone delayed-release tablet / Generic mfg.
Una época apasionante. Me ha encantado el vídeo que has colgado esta mañana. Gracias a los que peleais en primera línea de fuego (mejor dicho, de rayos :-) @jfcdrr , @marslain , @inf_entropy , @AmadeoWals (Twitter) - Jul 30, 2022
- | Venclexta (venetoclax) / Roche, AbbVie, Walter and Eliza Hall Institute
Trial initiation date: NCI-2021-09185: Venetoclax and a Pediatric-Inspired Regimen for the Treatment of Newly Diagnosed B Cell Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Jul 27, 2022
P1, N=6, Recruiting, Sponsor: City of Hope Medical Center
Trial completion date: May 2024 --> Jan 2025 | Trial primary completion date: May 2024 --> Dec 2024 Initiation date: Jun 2022 --> Mar 2022
- | Libtayo (cemiplimab-rwlc) / Regeneron
Trial completion date, Trial primary completion date, Metastases: CONTRAC: Cemiplimab in AlloSCT/SOT Recipients With CSCC (clinicaltrials.gov) - Jul 26, 2022
P1, N=12, Recruiting, Sponsor: Dana-Farber Cancer Institute
Initiation date: Jun 2022 --> Mar 2022 Trial completion date: Jul 2023 --> Jan 2024 | Trial primary completion date: Jul 2022 --> Jan 2023
- | Enrollment closed, Phase classification: AHOD03P1: Treating Young Patients With Newly Diagnosed, Low Stage, Lymphocyte Predominant Hodgkin Disease (clinicaltrials.gov) - Jul 14, 2022
P2, N=188, Active, not recruiting, Sponsor: Children's Oncology Group
Trial completion date: Jul 2023 --> Jan 2024 | Trial primary completion date: Jul 2022 --> Jan 2023 Unknown status --> Active, not recruiting | Phase classification: PN/A --> P2
- | Zynyz (retifanlimab-dlwr) / Incyte, Monjuvi (tafasitamab-cxix) / Incyte
New P1/2 trial, Combination therapy: Tafasitamab, Retifanlimab, and Rituximab in Combination With Chemotherapy (Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone) for the Treatment of Diffuse Large B-cell Lymphoma (clinicaltrials.gov) - Jul 13, 2022
P1/2, N=35, Not yet recruiting, Sponsor: University of Washington
- || Monjuvi (tafasitamab-cxix) / MorphoSys, Xencor, Incyte, Specialised Therap, Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
New P2 trial: Chemotherapy (DA-EPOCH+/-R) and Targeted Therapy (Tafasitamab) for the Treatment of Newly-Diagnosed Philadelphia Chromosome Negative B Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Jul 12, 2022
P2, N=30, Not yet recruiting, Sponsor: University of Washington
- | Opdivo (nivolumab) / Ono Pharma, BMS
Trial completion date, Trial primary completion date, Combination therapy: Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma (clinicaltrials.gov) - Jun 14, 2022
P3, N=192, Recruiting, Sponsor: National Cancer Institute (NCI)
Unknown status --> Active, not recruiting | Phase classification: PN/A --> P2 Trial completion date: Jun 2026 --> Jun 2028 | Trial primary completion date: Jun 2026 --> Jun 2028
- | lenalidomide / Generic mfg.
Trial completion date, Trial primary completion date, Combination therapy, IO biomarker: Testing the Addition of an Anti-cancer Drug, Lenalidomide, to the Usual Combination Chemotherapy Treatment ("EPOCH") for Adult T-Cell Leukemia-Lymphoma (ATL) (clinicaltrials.gov) - Jun 9, 2022
P1, N=30, Recruiting, Sponsor: National Cancer Institute (NCI)
Trial completion date: Jun 2026 --> Jun 2028 | Trial primary completion date: Jun 2026 --> Jun 2028 Trial completion date: Jun 2022 --> Jun 2023 | Trial primary completion date: Jun 2022 --> Jun 2023
- | Adcetris (brentuximab vedotin) / Takeda, Pfizer
Trial completion date, Trial primary completion date: P30CA033572: Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With CD30-Positive Peripheral T-cell Lymphoma (clinicaltrials.gov) - Jun 6, 2022
P2, N=48, Active, not recruiting, Sponsor: City of Hope Medical Center
Trial completion date: Jun 2022 --> Jun 2023 | Trial primary completion date: Jun 2022 --> Jun 2023 Trial completion date: May 2022 --> May 2023 | Trial primary completion date: May 2022 --> May 2023
- | Blincyto (blinatumomab) / Astellas, Amgen
Trial completion date, Trial primary completion date: SWOG-S1318: Blinatumomab and Combination Chemotherapy or Dasatinib, Prednisone, and Blinatumomab in Treating Older Patients With Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Jun 3, 2022
P2, N=58, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Trial completion date: May 2022 --> May 2023 | Trial primary completion date: May 2022 --> May 2023 Trial completion date: Jun 2022 --> Jun 2023 | Trial primary completion date: Jun 2022 --> Jun 2023
- | Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
Trial completion date, Trial primary completion date, Checkpoint inhibition, Checkpoint block, Metastases: Tacrolimus, Nivolumab, and Ipilimumab in Treating Kidney Transplant Recipients With Selected Unresectable or Metastatic Cancers (clinicaltrials.gov) - Jun 1, 2022
P1, N=16, Suspended, Sponsor: National Cancer Institute (NCI)
Trial completion date: Jun 2022 --> Jun 2023 | Trial primary completion date: Jun 2022 --> Jun 2023 Trial completion date: May 2022 --> May 2023 | Trial primary completion date: May 2022 --> May 2023
- |||| prednisone delayed-release tablet / Generic mfg.
Conocemos que tener menos pigmento en la piel significa que tienes menos protección contra la rayos UV perjudicial. Si tienes cabello rubio o pelirrojo, ojos claros y pecas o te quemas fácilmente con el sol, es más fácil que desarrolles un melanoma que alguien con tez más oscura. (Twitter) - May 30, 2022
- | prednisone delayed-release tablet / Generic mfg.
Journal: Mónico Sánchez Moreno: A pioneer in radiologic technology. (Pubmed Central) - May 10, 2022
Her efforts made it possible to have an affordable device made in Spain that would allow radiological examinations to be done in places where it would have been otherwise unthinkable. In conclusion, Mónico Sánchez Moreno was a self-made woman who deserves to be remembered for her pioneering role in portable radiology.
- | Kesimpta (ofatumumab subcutaneous) / Novartis, Genmab, Arzerra (ofatumumab) / Novartis, Genmab, Rituxan (rituximab) / Biogen, Zenyaku Holdings, Roche
Enrollment closed, Combination therapy: NCI-2014-01707: Dose Adjusted EPOCH Regimen in Combination With Ofatumumab or Rituximab in Treating Patients With Newly Diagnosed or Relapsed or Refractory Burkitt Lymphoma or Relapsed or Refractory Acute Lymphoblastic Leukemia (clinicaltrials.gov) - May 6, 2022
P2, N=40, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
In conclusion, Mónico Sánchez Moreno was a self-made woman who deserves to be remembered for her pioneering role in portable radiology. Recruiting --> Active, not recruiting
- | Jakafi (ruxolitinib) / Incyte
Trial termination: Ruxolitinib Phosphate or Dasatinib With Chemotherapy in Treating Patients With Relapsed or Refractory Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia (clinicaltrials.gov) - May 2, 2022
P2, N=11, Terminated, Sponsor: M.D. Anderson Cancer Center
Recruiting --> Active, not recruiting Completed --> Terminated; Study was closed early due to low accrual and lack of response.
- || prednisone delayed-release tablet / Generic mfg.
Lo vimos hace tiempo pero no da mucha esperanza = que Lu177 q no funcionó parece. Investigando vimos q supuestamente pueden dar buen resultado rayos no muy agresivos para lograr (con mucha suerte) efecto abscopal + Tils. (Lo explico como puedo ya que no soy médica) cont. (Twitter) - Apr 30, 2022
- | Yonsa (abiraterone acetate) / Churchill Pharma, Sun Pharma, Erleada (apalutamide) / J&J
Biomarker, Trial completion date, Trial primary completion date, Metastases: NCI-2018-01054: Apalutamide, Abiraterone Acetate, and Prednisone in Treating Participants With Metastatic Castration Resistant Prostate Cancer (clinicaltrials.gov) - Apr 29, 2022
P2, N=60, Suspended, Sponsor: M.D. Anderson Cancer Center
Completed --> Terminated; Study was closed early due to low accrual and lack of response. Trial completion date: Oct 2021 --> Oct 2022 | Trial primary completion date: Oct 2021 --> Oct 2022
- | prednisone delayed-release tablet / Generic mfg.
Trial completion, Phase classification, Trial completion date, Trial primary completion date: GWIIRT: Gulf War Illness Inflammation Reduction Trial (clinicaltrials.gov) - Apr 14, 2022
P2, N=83, Completed, Sponsor: Minneapolis Veterans Affairs Medical Center
Trial completion date: Oct 2021 --> Oct 2022 | Trial primary completion date: Oct 2021 --> Oct 2022 Recruiting --> Completed | Phase classification: P3 --> P2 | Trial completion date: Oct 2020 --> Mar 2022 | Trial primary completion date: Jan 2020 --> Dec 2021
- | Calquence (acalabrutinib) / AstraZeneca
Enrollment open: Modified VR-CAP and Acalabrutinib as First Line Therapy for the Treatment of Transplant-Eligible Patients With Mantle Cell Lymphoma (clinicaltrials.gov) - Mar 23, 2022
P2, N=45, Recruiting, Sponsor: Academic and Community Cancer Research United
Recruiting --> Completed | Phase classification: P3 --> P2 | Trial completion date: Oct 2020 --> Mar 2022 | Trial primary completion date: Jan 2020 --> Dec 2021 Not yet recruiting --> Recruiting
- | Zolinza (vorinostat) / Merck (MSD), Rituxan (rituximab) / Biogen, Zenyaku Holdings, Roche
Trial completion: Vorinostat and Combination Chemotherapy With Rituximab in Treating Patients With HIV-Related Diffuse Large B-Cell Non-Hodgkin Lymphoma or Other Aggressive B-Cell Lymphomas (clinicaltrials.gov) - Mar 15, 2022
P2, N=107, Completed, Sponsor: National Cancer Institute (NCI)
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- | Yonsa (abiraterone acetate) / Churchill Pharma, Sun Pharma
New P1 trial: Decreasing Dosing Regimens of Abiraterone 500 mg in Men With Prostate Cancer to Find Lowest Recommended Dose. (clinicaltrials.gov) - Mar 10, 2022
P1, N=50, Not yet recruiting, Sponsor: University of Chicago
- ||| itacitinib (INCB039110) / Incyte
Trial primary completion date: GRAVITAS-309: Itacitinib and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease (clinicaltrials.gov) - Mar 10, 2022
P2/3, N=157, Active, not recruiting, Sponsor: Incyte Corporation
Active, not recruiting --> Completed Trial primary completion date: Jan 2024 --> Apr 2024
- | Venclexta (venetoclax) / Roche, AbbVie, Walter and Eliza Hall Institute
Enrollment open, Trial initiation date: NCI-2021-09185: Venetoclax and a Pediatric-Inspired Regimen for the Treatment of Newly Diagnosed B Cell Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Mar 8, 2022
P1, N=6, Recruiting, Sponsor: City of Hope Medical Center
Trial primary completion date: Jan 2024 --> Apr 2024 Not yet recruiting --> Recruiting | Initiation date: Feb 2022 --> Jun 2022
- | Monjuvi (tafasitamab-cxix) / MorphoSys, Xencor, Incyte, Specialised Therap, Rituxan (rituximab) / Biogen, Zenyaku Holdings, Roche, Calquence (acalabrutinib) / AstraZeneca
Enrollment open, Trial initiation date: Rituximab, Lenalidomide, Acalabrutinib, Tafasitamab Alone and With Combination Chemotherapy for the Treatment of Newly Diagnosed Non-germinal Center Diffuse Large B-Cell Lymphoma, Smart Stop Study (clinicaltrials.gov) - Mar 4, 2022
P2, N=60, Recruiting, Sponsor: M.D. Anderson Cancer Center
Not yet recruiting --> Recruiting | Initiation date: Feb 2022 --> Jun 2022 Not yet recruiting --> Recruiting | Initiation date: Oct 2021 --> Mar 2022
- | Blincyto (blinatumomab) / Astellas, Amgen
Trial completion date, Trial primary completion date: ECOG-ACRIN E1910: Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Mar 2, 2022
P3, N=488, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Not yet recruiting --> Recruiting | Initiation date: Oct 2021 --> Mar 2022 Trial completion date: Jun 2022 --> Sep 2025 | Trial primary completion date: Jun 2022 --> Sep 2025
- | prednisone delayed-release tablet / Generic mfg.
Journal: The hilum of the lung: Two classical radiological signs to decipher it. (Pubmed Central) - Feb 26, 2022
This article reviews the literature and describes the principal anatomic relations of the lung hilum through illustrative cases to enable the two most important radiologic signs to be identified: "hilum overlay" and "hilum convergence". In the initial imaging evaluation of patients with cardiothoracic disease, knowledge of these basic principles facilitates the three-dimensional location of lesions in a single-plane image, optimizing time and resources.
- || prednisone delayed-release tablet / Generic mfg.
Review: A chronic encapsulated expanding hematoma that developed 15 years after gamma knife surgery for a cerebral arteriovenous malformation: A case report and review of the literature. (Pubmed Central) - Feb 24, 2022
The final diagnosis was a secondary chronic encapsulated expanding hematoma after GKS. This is the first report to show the early-stage imaging findings of this late effect after GKS.
- | Brukinsa (zanubrutinib) / BeiGene, Rituxan (rituximab) / Roche
Enrollment open, Combination therapy: Zanubrutinib in Combination With R-CHOP (ZaR-CHOP) for Newly Diagnosed Diffuse Large B-Cell Lymphoma (clinicaltrials.gov) - Feb 24, 2022
P1, N=24, Recruiting, Sponsor: Yazeed Sawalha
This is the first report to show the early-stage imaging findings of this late effect after GKS. Suspended --> Recruiting
- | Elzonris (tagraxofusp) / Menarini, Nippon Shinyaku
Enrollment open: Tagraxofusp and Low-Intensity Chemotherapy for the Treatment of CD123 Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma (clinicaltrials.gov) - Feb 18, 2022
P1/2, N=40, Recruiting, Sponsor: M.D. Anderson Cancer Center
Suspended --> Recruiting Not yet recruiting --> Recruiting
- | Rituxan (rituximab) / Roche
Trial completion date: Rituximab and Combination Chemotherapy With or Without Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Diffuse Large B Cell Lymphoma (clinicaltrials.gov) - Feb 15, 2022
P2, N=349, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Not yet recruiting --> Recruiting Trial completion date: Dec 2021 --> Dec 2022
- | Ukoniq (umbralisib) / TG Therap, Gazyva (obinutuzumab) / Roche, Biogen
Trial suspension: SWOG S1608: Obinutuzumab With or Without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma (clinicaltrials.gov) - Feb 11, 2022
P2, N=103, Suspended, Sponsor: National Cancer Institute (NCI)
Trial completion date: Dec 2021 --> Dec 2022 Recruiting --> Suspended
- | prednisone delayed-release tablet / Generic mfg.
Si no lo ha evaluado, ¿ como rayos va a aprobar el producto?...no tiene sentido lo que afirmas. (Twitter) - Feb 9, 2022
- ||||| itacitinib (INCB039110) / Incyte
Enrollment closed, Enrollment change: GRAVITAS-309: Itacitinib and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease (clinicaltrials.gov) - Jan 21, 2022
P2/3, N=157, Active, not recruiting, Sponsor: Incyte Corporation
Recruiting --> Suspended Recruiting --> Active, not recruiting | N=431 --> 157
- | Adcetris (brentuximab vedotin) / Seagen, Takeda
Trial completion date: AHOD1331: Brentuximab Vedotin and Combination Chemotherapy in Treating Children and Young Adults With Stage IIB, Stage IIIB, IVA, or IVB Hodgkin Lymphoma (clinicaltrials.gov) - Jan 19, 2022
P3, N=597, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting | N=431 --> 157 Trial completion date: Dec 2021 --> Jan 2023
- | abiraterone acetate / Generic mfg.
Biomarker, Trial completion date, Trial primary completion date: Pharmacogenomics IND EXEMPT SNP Clinical Study - Abiraterone and Single Nucleotide Polymorphisms (clinicaltrials.gov) - Jan 14, 2022
P1, N=20, Active, not recruiting, Sponsor: Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair
Trial completion date: Dec 2021 --> Jan 2023 Trial completion date: Jul 2022 --> Mar 2022 | Trial primary completion date: Jun 2022 --> Mar 2022
- || Venclexta (venetoclax) / Roche, AbbVie, Blincyto (blinatumomab) / Astellas, Amgen, Rituxan (rituximab) / Roche
Trial initiation date, Combination therapy: NCI-2021-01791: Venetoclax, Dasatinib, Prednisone, Rituximab and Blinatumomab for the Treatment of Newly Diagnosed or Relapsed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia or Mixed Phenotype Acute Leukemia (clinicaltrials.gov) - Jan 13, 2022
P1, N=20, Not yet recruiting, Sponsor: OHSU Knight Cancer Institute
Trial completion date: Jul 2022 --> Mar 2022 | Trial primary completion date: Jun 2022 --> Mar 2022 Initiation date: Aug 2021 --> Feb 2022
- | Venclexta (venetoclax) / Roche, AbbVie, Walter and Eliza Hall Institute
Trial completion date, Trial primary completion date: NCI-2021-09185: Venetoclax and a Pediatric-Inspired Regimen for the Treatment of Newly Diagnosed B Cell Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Jan 11, 2022
P1, N=6, Not yet recruiting, Sponsor: City of Hope Medical Center
Initiation date: Aug 2021 --> Feb 2022 Trial completion date: Oct 2023 --> May 2023 | Trial primary completion date: Oct 2023 --> May 2023
- | Ukoniq (umbralisib) / TG Therap, Gazyva (obinutuzumab) / Roche, Biogen
Enrollment change: SWOG S1608: Obinutuzumab With or Without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma (clinicaltrials.gov) - Dec 21, 2021
P2, N=103, Recruiting, Sponsor: National Cancer Institute (NCI)
Trial completion date: Oct 2023 --> May 2023 | Trial primary completion date: Oct 2023 --> May 2023 N=150 --> 103
- | prednisone delayed-release tablet / Generic mfg.
Journal: Marie Curie: How to break the glass ceiling in science and in radiology. (Pubmed Central) - Dec 16, 2021
Being the first woman to break through so many barriers in a totally male-dominated science makes her an emblematic figure in the fight for equal opportunities and human rights. This article reviews her most important contributions to science in general and to diagnostic radiology in particular through her participation in the French military's radiological plan during the First World War.
- | Venclexta (venetoclax) / Roche, AbbVie, Walter and Eliza Hall Institute
New P1 trial: NCI-2021-09185: Venetoclax and a Pediatric-Inspired Regimen for the Treatment of Newly Diagnosed B Cell Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Dec 14, 2021
P1, N=6, Not yet recruiting, Sponsor: City of Hope Medical Center
- | nelarabine / Generic mfg.
Trial completion date, Trial primary completion date: Combination Chemotherapy and Nelarabine in Treating Patients With T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma (clinicaltrials.gov) - Dec 9, 2021
P2, N=160, Recruiting, Sponsor: M.D. Anderson Cancer Center
This article reviews her most important contributions to science in general and to diagnostic radiology in particular through her participation in the French military's radiological plan during the First World War. Trial completion date: Oct 2021 --> Oct 2022 | Trial primary completion date: Oct 2021 --> Oct 2022
- | prednisone delayed-release tablet / Generic mfg.
Trial completion date, Metastases: Cryotherapy in Treating Patients With Primary Stage I Non-Small Cell Lung Cancer or Lung Metastasis (clinicaltrials.gov) - Nov 3, 2021
P1, N=9, Active, not recruiting, Sponsor: Barbara Ann Karmanos Cancer Institute
Trial completion date: Oct 2021 --> Oct 2022 | Trial primary completion date: Oct 2021 --> Oct 2022 Trial completion date: Dec 2020 --> Dec 2022
- prednisone delayed-release tablet / Generic mfg.
[VIRTUAL] Contour Connections: Early Interest in a Program to Connect International Radiation Oncologists for Virtual Cloud-Based Contouring and Treatment Plan Evaluation (McCormick Place West, Outside Room W375) - Oct 30, 2021 - Abstract #ASTRO2021ASTRO_770;
Contour Connections seeks to address this demand by actively recruiting individuals to utilize a virtual cloud-based platform to review contours and treatment plans with each other. This study demonstrates that recruitment is readily feasible within the global radiation oncology community, with early results showing a favorable participant experience.
- prednisone delayed-release tablet / Generic mfg.
[VIRTUAL] Building capacity for high quality HDR Brachytherapy: Rayos Contra Cancer - Train the Trainers (McCormick Place West, Room W185 a/b/c/d) - Oct 30, 2021 - Abstract #ASTRO2021ASTRO_511;
- prednisone delayed-release tablet / Generic mfg.
[VIRTUAL] International 03 - Bridging the Gap: Highlighting Efforts to Build Radiation Oncology Capacity Globally (McCormick Place West, Room W185 a/b/c/d) - Oct 30, 2021 - Abstract #ASTRO2021ASTRO_508;
Li, a resident in radiation oncology at UCSF and founding director of the Rayos Contra Cancer organization, will discuss their efforts to create sustainable solutions to address the global burden of cancer...Be sure to log in. Identify barriers to access radiotherapy in limited resource regions Identify barriers to global research partnerships in radiation oncology Discuss ongoing efforts to build capacity in LMICs in radiation oncology